Evidence map›Paper›PMID 10329750›Full record

ArticleJournal of neurology, neurosurgery, and psychiatry1999

Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic.

M W Kellett, D F Smith, P A Stockton, D W Chadwick

Abstract read
In one paragraph

Article in Journal of neurology, neurosurgery, and psychiatry, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Epilepsy and suicide: pathogenesis, risk factors, and prevention.Neuropsychiatric disease and treatment · 2008
    Article
  5. Psychopharmacology of topiramate: from epilepsy to bipolar disorder.Neuropsychiatric disease and treatment · 2006
    Article
  6. The promise of new antiepileptic drugs.British journal of clinical pharmacology · 2002
    Review
  7. Review
  8. Effects of topiramate on cognitive function.Journal of neurology, neurosurgery, and psychiatry · 2000
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

M W KellettThe Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool L9 7LJ, UK.
D F Smith
P A Stockton
D W Chadwick

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTopiramate became available for use in October 1995. Meta-analysis of its randomised controlled data suggested that it may be the most potent of the new antiepileptic drugs. The aim of this study was to assess the first year's postlicensing experience in a specialist regional epilepsy clinic.

methodsThe case notes of 174 of 178 patients who were prescribed topiramate in the 12 months between November 1995 and October 1996 were retrospectively reviewed. Data were collected on seizure type, classification of epilepsy, presence or absence of learning difficulties, depression, or behavioural problems, co-medication, dosage escalation, efficacy, adverse events, whether or not the patient was still on topiramate and, if not, the reason for withdrawal. Kaplan-Meier survival analysis was used to estimate the overall retention rate and log rank tests were used to determine factors associated with stopping topiramate.

resultsOverall 90 of 174 patients had ceased taking topiramate at the end of the study. The median "survival time" was 427 days (95% CI 362.9-491.1). The cumulative probability for remaining on topiramate at 1 year was 0.549 (95% CI 0.475-0.623). The retention rate in patients in whom topiramate was substituted for another drug was significantly higher than in those in whom it was added to current therapy. Adverse events (CNS related) were the most common reason for stopping topiramate. Eight patients with partial and one patient with juvenile myoclonic epilepsy became seizure free.

conclusionsThere is a significant (20-25%) chance of being intolerant to topiramate at relatively low doses. Substituting topiramate for another antiepileptic drug may reduce the chances of drug withdrawal. If topiramate is tolerated there is a good chance of worthwhile improvement in seizure control. These data, although not derived from randomised controlled trials, represent pragmatic use of novel antiepileptic drugs in "real life" and may be helpful to non-specialists when prescribing topiramate.

Indexed as

AnticonvulsantsEpilepsyFemaleFructoseHumansMalePractice Patterns, Physicians'Time FactorsTopiramateAnticonvulsantsFructoseTopiramate

Identifiers

PMID10329750
PMCPMC1736381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.